Category: South Africa

Foothill Ranch, Calif., June 16, 2022 (GLOBE NEWSWIRE) — To tackle the infant formula crisis, producers can rely on Southern California supplement solutions contract manufacturer ProTab Laboratories to blend custom premixes and produce and package infant formula with a rapid turnaround time.

“ProTab is in the perfect position as a supplement solution manufacturer and packager to prioritize infant formula production with safety and scale to help replenish the supply in the market,” said Joanne Hsu, vice president of operations. “We are ready to produce safe, high-quality premixes with careful processing and top-quality standards at our facility for reassuring parents and babies that they will have access to quality and safe infant formula.”

Safety continues to be at the forefront of the crisis. ProTab has the capabilities of in-house analytical laboratory services for quality control validation, including analytical capabilities. The company is FDA registered with cGMP, FSMA, and FSSC 22000 certified by NSF.

“ProTab can rapidly turn around the production of powder and premix for liquid infant formula at a large scale to bolster the supply of products with proper FDA-inspected nutritional values and safety,” said Hsu. “Our certifications are the gold standard of safety for reassuring our manufacture of food and supplement solutions, including infant formula premix solutions.”

“As a GFSI certified producer and packager of supplement solutions, ProTab elevates food safety to the next level with our state-of-the-art facility, coupled with our quality control procedures and testing,” said Fariba Samadi, director of quality assurance and regulatory affairs. “Following stringent quality assurance and safety processes, we evaluate the quality of raw materials before manufacturing as well as the finished goods.”

Infant formula producers can leverage ProTab’s modern technology for precision blending needed for producing infant formula. Microencapsulation is offered to mask the undesirable characteristics of particular additives and formula ingredients. The technology is part of ProTab’s recent multimillion-dollar expansion to increase the footprint for blending and mixing premix solutions.

ProTab can also help secure the best materials and ingredients if needed; the company keeps up with the newest production and delivery technologies and the latest regulatory requirements and considers modern formulation and consumer trends.

For specific needs in labeling and standards, ProTab Labs can manufacture products to the specification of USDA Organic, Non-GMO Project Verified, Halal, and Kosher. The company is registered with Health Canada as a foreign manufacturer site.

“We encourage infant formula manufacturers and brand holders to bring their formulas and packaging schematics to work with us,” said Hsu. “We are confident in helping everyone get through the bottleneck together and positioning ProTab as a long-term infant formula production partner,” said Hsu.

About ProTab Laboratories
ProTab Laboratories is a custom research contract manufacturer operating a state-of-the-art facility in Southern California for providing rapid turnaround services for tablet, capsule, and powder form products, along with high-capacity mixing processes for nutritional and dietary supplements, tableting, microencapsulation, granulation, and milling. ProTab can guide brands through the product development and technical process from inception to the final product.

Contact us at info@protablabs.com.

For brands that would like to strengthen their vendor diversity profile, ProTab is also a certified Women-Owned Business Enterprise.

Certifications
ProTab’s manufacturing operation is fully compliant with all current Good Manufacturing Practices (cGMP) established within the industry and meets or exceeds all quality standards for Nutritional Supplements. The company has established Standard Operating Procedures (SOP) to ensure that this standard is met in all manufacturing process phases. Our quality control standards are compliant with Kosher, Halal, Health Canada, USDA Organic, State of California Department of Public Health, NSF, and Non-GMO Project Verified.

Attachments

• ProTab Labs responds to infant formula crisis
• ProTab Labs prioritizes infant formula production solutions

Ana Arakelian, Head of Public Relations and Communications
ProTab Laboratories
949.635.1930
pr@protablabs.com

‘Value Creation in the Metaverse’ report examines the massive, global impact of the metaverse across key sectors and businesses

NEW YORK and LONDON and PARIS, June 15, 2022 (GLOBE NEWSWIRE) — McKinsey & Company released its new report “Value creation in the metaverse,” which shows the metaverse may be too big to ignore. McKinsey’s preliminary forecast shows the metaverse has the potential to grow up to $5 trillion in value by 2030. It shows e-commerce as the largest economic force ($2.6 trillion), ahead of sectors such as virtual learning ($270 billion), advertising ($206 billion), and gaming ($125 billion).

As companies of all different shapes and sizes look to enter the metaverse, this extensive report provides a clear view of what the metaverse is and is not, what first movers are doing, what’s fueling the investment, and the potential for consumer and B2B companies.

The report builds on multiple proprietary insights and analysis, including a survey of more than 3,400 consumers and executives on adoption of the metaverse, its potential, and its likely impact on behavior. The researchers also interviewed metaverse builders and industry experts.

“The metaverse represents a strategic inflection point for companies, and it presents a significant opportunity to influence the way we live, connect, learn, innovate, and collaborate,” said Eric Hazan, senior partner, McKinsey & Company. “Our ambition is to help leaders of both consumer and B2B companies better understand its power and potential, identify strategic imperatives, and act as a force for its evolution.”

What’s fueling the metaverse investment
Already this year, companies, venture capital, and private equity firms have invested more than $120 billion in the metaverse—more than double the $57 billion invested in all of last year.

Multiple factors are driving this investor enthusiasm:

• ongoing technological advances across the infrastructure required to power the metaverse
• demographic tailwinds
• increasingly consumer-led brand marketing and engagement
• increasing marketplace readiness as users explore today’s version of the metaverse, which is largely driven by gaming while applications emerge in socializing, fitness, commerce, virtual learning, and other uses

Already, more than three billion gamers worldwide have access to different versions of the metaverse.

“While the idea of connecting virtually has been decades in the making, it is now increasingly real, meaning real people are using it and spending real money and companies are betting big,” said Lareina Yee, senior partner, McKinsey & Company. “Yet this booming interest has made it difficult to separate hype from reality. It’s worth remembering that while the bust of the first dot-com boom resulted in the disappearance of scores of companies, the internet itself went from strength to strength, giving rise to new entrants.”

Consumers are already engaging in the metaverse
Consumers are already there. McKinsey’s research shows consumers are excited about transitioning life into the metaverse, with almost six in ten (59%) consumers preferring at least one metaverse experience over its physical alternative.

Among those consumers, certain types of activities stand out for being most preferred in the immersive world:

• shopping—purchasing physical or virtual goods (79%)
• attending virtual social events or playing social games (78%)
• exercising using virtual reality (76%)

Senior leaders believe the metaverse will have a significant impact on their industry
Business leaders see the metaverse’s potential to drive impact and margin growth. Ninety-five percent of leaders say they expect the metaverse to have a positive impact on their industry within five to ten years, with 31 percent saying the metaverse will fundamentally change the way their industry operates. More significantly, a quarter of leaders expect the metaverse technology to drive more than 15 percent of their organization’s total margin growth in the next five years.

“The metaverse has put us at the cusp of the next wave of digital disruption,” said Tarek Elmasry, senior partner, McKinsey & Company. “It’s transformative. It will likely have a major impact on our commercial and personal lives, which is why businesses, policy makers, consumers, and citizens may want to explore and understand as much as they can about this phenomenon, the technology that will underpin it, and the ramifications it could have for our economies and wider society.”

For more insights and to read the full report, please click here.

About the report
McKinsey surveyed more than 3,400 consumers and senior executives across Asia–Pacific, China, Europe, and the United States to gain insight into the habits of current metaverse users—their motivations, what they are doing, and what they expect to do. In analyzing the metaverse’s value-creation potential and total investment landscape, we examined the drivers of activity among major corporations, venture capital, and private-equity funds. We examined the potential impact of the metaverse on sectors most closely tied to its technology and uses, supplementing our work with additional research, case studies, and real-world examples. The report also includes an in-depth analysis of five industries: apparel, fashion, and luxury; consumer packaged goods; financial services; retail; and telecommunications, media, and technology.

About McKinsey & Company
McKinsey & Company is a global management consulting firm committed to helping organizations realize sustainable, inclusive growth. We work with clients across the private, public, and social sectors to solve complex problems and create positive change for all their stakeholders. We combine bold strategies and transformative technologies to help organizations innovate more sustainably, achieve lasting gains in performance, and build workforces that will thrive for in this generation and the next.

About Growth, Marketing & Sales, McKinsey & Company
The mission of McKinsey’s Growth, Marketing & Sales Practice is to help leaders of both consumer and business-to-business clients create Growth That Matters through meaningful transformations and marketing-driven profit. The practice helps its clients set their strategic direction, develop their marketing and sales capabilities, and connect their organization to realize the full potential of today’s omnichannel opportunities. Clients benefit from McKinsey’s experience in core areas of growth, marketing and sales such as growth strategy, branding, customer insights, marketing ROI, digital marketing, CLM, pricing, and sales and channel management.

For more information, please contact
US media contact: MaryLiz Ghanem, DiGennaro Communications, McKinsey-DiGennaro@digennaro-usa.com, +1 917 518 8422

UK media contact: Ruth Jones, 3THINKRS, mckinsey@3thinkrs.com, +44 0208 0872843

Global document solutions provider to use Anaqua’s AQX platform to help manage and optimize its extensive patent portfolio

BOSTON, June 14, 2022 (GLOBE NEWSWIRE) — Anaqua, the leading provider of innovation and intellectual property management solutions, today announced that global document solutions provider Kyocera Document Solutions Inc. has selected Anaqua’s AQX platform for integrated management of the company’s extensive patent portfolio.

Headquartered in Osaka, Japan, Kyocera Document Solutions Inc. provides customers worldwide with a range of products, business applications, and consultative services to optimize and manage their document workflow, greatly enhancing operational efficiency.

Kyocera Document Solutions Inc. chose Anaqua’s AQX Corporate platform as its primary patent management system with patent annuity payments from Anaqua Services fully integrated to unify patent management and payment management. Through this integrated functionality of the AQX Corporate platform and the availability of detailed, up-to-the-minute data visualization dashboards, Kyocera Document Solutions Inc. will be able to better manage, maintain and optimize the value of its portfolio.

“We were looking for an integrated approach that would enable us to manage our patent portfolio more efficiently and holistically,” said General Manager of Legal and Intellectual Property Division, Seitaro Yoshida of Kyocera Document Solutions Inc. “AQX’s comprehensive intellectual property management platform enabled global IP management for us. During implementation, Anaqua and Kyocera Document Solutions Inc. worked closely together to build up a new workflow. Anaqua listened and were responsive to our needs, enabling us to achieve the best fit for our operations.”

“We are delighted to have been selected by Kyocera Document Solutions Inc. to help them manage their IP as the company continues in its goal of helping other organizations around the world put knowledge to work to drive change,” said Bob Romeo, CEO of Anaqua. “The agreement not only reflects our strength in the business solutions sector, but also our increasing role in the Japanese market, where more and more companies are entrusting Anaqua with their IP management.”

About Anaqua
Anaqua, Inc. is a premium provider of integrated intellectual property (IP) management technology solutions and services for corporations and law firms. Its IP management software solutions, AQX and PATTSY WAVE, both offer best practice workflows with big data analytics and tech-enabled services to create an intelligent environment designed to inform IP strategy, enable IP decision-making, and streamline IP operations, tailored to each segment’s need. Today, nearly half of the top 100 U.S. patent filers and global brands, as well as a growing number of law firms worldwide use Anaqua’s solutions. Over one million IP executives, attorneys, paralegals, administrators, and innovators use the platform for their IP management needs. The company’s global operations are headquartered in Boston, with offices across the U.S., Europe, and Asia. For additional information, please visit anaqua.com, or on LinkedIn.

About Kyocera Document Solutions Inc.
Kyocera Document Solutions Inc. is a global leading provider of total document solutions based in Osaka, Japan. The company’s portfolio includes reliable and eco-friendly MFPs and printers, as well as business applications and consultative services which enable customers to optimize and manage their document workflow, reaching new heights of efficiency. With professional expertise and a culture of empathetic partnership, the objective of the company is to help organisations put knowledge to work to drive change.

Kyocera Document Solutions Inc. is a group company of Kyocera Corporation (Kyocera), a leading supplier of semiconductor packages, industrial and automotive components, semiconductor packages, electronic devices, smart energy systems, printers, copiers, and mobile phones. During the year ended March 31, 2022, the Kyocera Group’s consolidated sales revenue totaled 1.8 trillion yen (approx. US$15.1 billion). Kyocera is ranked #665 on Forbes magazine’s 2022 “Global 2000” list of the world’s largest publicly traded companies, and has been named by The Wall Street Journal among “The World’s 100 Most Sustainably Managed Companies.”

Company Contact:
Amanda Hollis
Communications Director
Anaqua
617-375-2626
ahollis@Anaqua.com

MARLTON, N.J., June 14, 2022 (GLOBE NEWSWIRE) — Impulse Dynamics, a commercial-stage medical device company focused on delivering our CCM therapy to people with heart failure, announced that the first implants in Europe for the newly launched Optimizer® Smart Mini device were recently completed in Italy. The company announced the launch of the new technology on April 29, 2022, and the first U.S. implants on May 10, 2022.

Dr. Stefano Guarracini, Head of Cardiology at the Synergo Casa di Cura Pierangeli Hospital in Pescara, Italy, described his experience with CCM therapy and his outlook for the Optimizer Smart Mini system after the first implant. “Starting in 2019, we had the opportunity to implant Optimizer devices in several patients with heart failure. We believe in the technology and consider CCM therapy to be the only option for many patients suffering from heart failure. We are excited now to be affiliated with the first European institution to have implanted the new Optimizer Smart Mini device and look forward to the simple but more advanced patient management experiences during implants and follow-ups going forward.”

Dr. Giovani Bisignani, with the Ospedale di Castrovillari, who completed his first implant almost simultaneously in the southern Italian province of Cosenza, said, “CCM therapy is a powerful weapon against heart failure. The cutting-edge technology of the new Optimizer Smart Mini along with its smaller, physiological shape allowed us to achieve efficient implantation and initiation of CCM therapy in even less time.”

In March 2022, the company announced that its quality management system received certification under the new European Union Medical Device Regulation. We believe that the launch of the Optimizer Smart Mini system is an example of the importance of a global infrastructure to support ongoing technology innovation and access. The new components of the Optimizer Smart Mini system are equally important across international markets, including a rechargeable battery with a 20-year life and new internal technology with improved programming and potential for remote monitoring in a smaller design to make the implant procedure easier for patients and physicians.

“The pace of this international rollout is a reflection of our commitment to delivering innovation that is relevant to patients worldwide,” said Mateusz Zelewski, MD, Impulse Dynamics’ Vice President International, “It is exciting to see how quickly we can increase access to new and better technology that offers hope for more patients living with heart failure.”

The Optimizer Smart Mini delivers CCM therapy, which consists of electric pulses applied to the heart between heartbeats and serves to enhance the performance of cardiac muscular contraction, making the heart work more efficiently without increasing the heart rate or the oxygen consumption of the cardiac muscle. CCM therapy is currently indicated in Europe to reduce hospitalizations and improve physical exercise tolerance, quality of life, and functional status for a large population of patients with systolic heart failure who remain symptomatic despite guideline-directed medical therapy.

To date, CCM therapy has already been used to treat over 7,000 patients worldwide and is available in 44 countries across the globe. The therapy has been studied in almost 2,000 patients and has appeared in more than 100 peer-reviewed journal articles. Ongoing studies are also underway to examine the safety and efficacy of CCM for patients suffering from heart failure with a left ventricular ejection fraction between 40 – 60%.

About Impulse Dynamics

Impulse Dynamics is dedicated to helping healthcare providers enhance the lives of people with heart failure by transforming how the condition is treated. The company is focused on delivering its proprietary CCM therapy, which is delivered by the company’s Optimizer Smart device, the CE-marked, and FDA-approved treatment verified to improve the quality of life for heart failure patients. CCM therapy is a safe, effective, and minimally invasive treatment option for many heart failure patients who otherwise have few effective options available to them.[1] To learn more, visit www.ImpulseDynamics.com, or follow the company on LinkedIn, Twitter, and Facebook.

Forward-looking Statements

This press release contains forward-looking statements. All statements other than statements of historical facts contained in this press release are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as ‘‘may,’’ ‘‘will,’’ ‘‘should,’’ ‘‘expect,’’ ‘‘plan,’’ ‘‘anticipate,’’ ‘‘could,’’ ‘‘intend,’’ ‘‘target,’’ ‘‘project,’’ ‘‘contemplate,’’ ‘‘believe,’’ ‘‘estimate,’’ ‘‘predict,’’ ‘‘potential’’ or ‘‘continue’’ or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements include, but are not limited to, statements concerning potential benefits of CCM therapy, and the absence of risks associated therewith; the ability for CCM therapy and our products to fill a significant unmet medical need for patients with heart failure; and the short-term and long-term benefits of the Optimizer Smart Mini and CCM therapy in patients with heart failure, as well as to the physicians treating those patients. These forward-looking statements are based on management’s current expectations and involve known and unknown risks and uncertainties that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Other important factors that could cause actual results, performance or achievements to differ materially from those contemplated in this press release include, without limitation: the company’s future research and development costs, capital requirements and the company’s needs for additional financing; commercial success and market acceptance of CCM therapy; the company’s ability to achieve and maintain adequate levels of coverage or reimbursement for Optimizer Smart and Optimizer Smart Mini systems or any future products the company may seek to commercialize; competitive companies and technologies in the industry; the company’s ability to expand its indications and develop and commercialize additional products and enhancements to its current products; the company’s business model and strategic plans for its products, technologies and business, including its implementation thereof; the company’s ability to expand, manage and maintain its direct sales and marketing organization; the company’s ability to commercialize or obtain regulatory approvals for CCM therapy and its products, or the effect of delays in commercializing or obtaining regulatory approvals; FDA or other U.S. or foreign regulatory actions affecting us or the healthcare industry generally, including healthcare reform measures in the United States and international markets; the timing or likelihood of regulatory filings and approvals; and the company’s ability to establish and maintain intellectual property protection for CCM therapy and products or avoid claims of infringement. The company does not undertake any obligation to update forward-looking statements and expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein. These forward-looking statements should not be relied upon as representing the company’s views as of any date subsequent to the date of this press release.

[1] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5494150/

Attachments

• Optimizer Smart Mini Delivery System
• Optimizer Smart Mini Delivery System With Leads to the Heart

Rex Richmond, Director (Media Relations)
Impulse Dynamics
856-642-9933
rrichmond@impulsedynamics.com

Harriss Currie, CFO (Investor Relations)
Impulse Dynamics
856-642-9933
hcurrie@impulsedynamics.com

Ian Segal, Public Relations
Impulse Dynamics
856-642-9933
isegal@impulsedynamics.com

TEMECULA, Calif., June 14, 2022 (GLOBE NEWSWIRE) — Nikkiso Cryogenic Industries’ Clean Energy & Industrial Gases Group (“Group”), a part of the Nikkiso Co., Ltd (Japan) group of companies, is pleased to announce that Ankur Arora has been named Product & Business Development Manager for Nikkiso Cryogenic Services serving Southeast Asia, New Zealand and Africa.

Ankur has broad global experience in over 30 countries and worked for nearly 20 years with Atlas Copco. His responsibilities included Business Development Manager and Global Sales & Marketing reporting to Germany, based in Auckland, New Zealand, Regional BDM & Application/Product Managers based in Shanghai. He has also served as Project Manager. A mechanical engineer, he also earned an MBA and is currently working on a DBA.

He will be responsible for the launch, sales and solutions related to Waste Heat Recovery and Organic Rankine Cycle Power Generation, Pressure Letdown Power Recovery and more. He will report to Emile Bado, Executive VP, Marketing, and Dr. Reza Agahi, Vice President of Turbo.

“Ankur’s industry and global market experience will be of great benefit to the Group, as we work to develop the opportunities in these regions,” according to Emile Bado, Executive Vice President, Marketing.

With this addition, Nikkiso continues their commitment to be both a global and local presence for their customers.

ABOUT CRYOGENIC INDUSTRIES
Cryogenic Industries, Inc. (now a member of Nikkiso Co., Ltd.) member companies manufacture and service engineered cryogenic gas processing equipment (pumps, turboexpanders, heat exchangers, etc.), and process plants for Industrial Gases, Natural gas Liquefaction (LNG), Hydrogen Liquefaction (LH2) and Organic Rankine Cycle for Waste Heat Recovery. Founded over 50 years ago, Cryogenic Industries is the parent company of ACD, Nikkiso Cryo, Nikkiso Integrated Cryogenic Solutions, Cosmodyne and Cryoquip and a commonly controlled group of approximately 20 operating entities.

For more information, please visit www.nikkisoCEIG.com and www.nikkiso.com.

MEDIA CONTACT:
Anna Quigley
+1.951.383.3314
aquigley@cryoind.com